ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636

Its studies are mostly in Breast Neoplasms, led by Ensem Therapeutics.

Furthest: phase 2, since May 1, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ensem Therapeutics11 open or runningphase 2since May 1, 2025May 1, 2025Jun 30, 2027phase 2 · NCT06993844

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2025First study: phase 2 study in NeoplasmsFirst studyNCT06993844 · 233 planned · United States, China

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in NeoplasmsNCT06993844

TargetBeta

PIK3CA →read by rule
“An orally bioavailable, pan-mutant selective inhibitor and degrader of the catalytic subunit of class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha), ”NCIt, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06993844Neoplasms · United States, China2RecruitingJun 30, 2027233

How it is read

Names in the registry

  • “ETX-636 dose escalation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.